CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue, net of contractual allowances and adjustments	$ 4,095	$ 3,448
less allowance for doubtful accounts	(968)	(584)
Net sales	3,127	2,864
Total cost of sales	2,908	2,639
Gross profit	219	225
OPERATING EXPENSES:
Operating expenses	9,623	9,452
Impairment of intangible assets and goodwill	1,590	4,685
TOTAL OPERATING EXPENSES	11,213	14,137
OPERATING LOSS	(10,994)	(13,912)
OTHER INCOME (EXPENSE):
Interest expense, net	(473)	(269)
Warrant revaluation	416	1,918
Loss on modification of warrants	(1,128)
Derivative revaluation	(415)	267
Gain on settlement of liability, net	1,437	263
(Loss) gain on extinguishment of debt	(20)	376
Loss on extinguishment of convertible notes		(2,903)
Loss on litigation	(266)
Loss on issuance of convertible notes	(1,870)	(1,328)
Loss on settlement of equity instruments		(385)
Total other expenses	(2,319)	(2,061)
LOSS BEFORE INCOME TAXES	(13,313)	(15,973)
INCOME TAX BENEFIT	70	279
NET LOSS	(13,243)	(15,694)
Deemed dividends related to beneficial conversion feature of preferred stock and fair value of consideration issued to induce conversion of preferred stock		(4,222)
TOTAL DIVIDENDS		(4,222)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (13,243)	$ (19,916)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)	$ (2.33)	$ (13.82)
BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)	5,695,159	1,441,113
Service revenue, net [Member]
Revenue, net of contractual allowances and adjustments	$ 4,051	$ 3,335
less allowance for doubtful accounts	(968)	(584)
Net sales	3,083	2,751
Total cost of sales	2,908	2,549
Clinical research grants [Member]
Revenue, net of contractual allowances and adjustments		100
Total cost of sales		90
Other [Member]
Revenue, net of contractual allowances and adjustments	$ 44	$ 13